Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|JNJ-26483327||BGB-102||EGFR Inhibitor (Pan) 47 HER2 Inhibitor 26 RET Inhibitor 39||JNJ-26483327 (BGB-102) is a multi-kinase inhbitor, which inhibits wild-type and mutant EGFR, RET, and has activity against VEGFR3, ERBB2 (HER2), ERBB4, and SRC family members (PMID: 20823884).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||stomach cancer||not applicable||JNJ-26483327||Preclinical||Actionable||In a preclinical study, human gastric cancer cells demonstrated sensitivity to JNJ-26483327 (PMID: 19584230).||19584230|
|Unknown unknown||Advanced Solid Tumor||not applicable||JNJ-26483327||Phase I||Actionable||In a Phase I clinical trial, JNJ-26483327 was well-tolerated in patients with a range of advanced solid tumors, and demonstrated preliminary anti-tumor activity with 32% (6/19) of patients achieving stable disease for greater than 2 cycles (PMID: 20823884).||20823884|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|